4//SEC Filing
Gollob Jared 4
Accession 0001193125-25-311503
CIK 0001815442other
Filed
Dec 7, 7:00 PM ET
Accepted
Dec 8, 6:09 PM ET
Size
18.0 KB
Accession
0001193125-25-311503
Insider Transaction Report
Form 4
Gollob Jared
Chief Medical Officer
Transactions
- Exercise/Conversion
Common Stock
2025-12-08$5.33/sh+49,307$262,806→ 159,299 total - Sale
Common Stock
2025-12-08$87.37/sh−13,759$1,202,139→ 145,540 total - Sale
Common Stock
2025-12-08$88.02/sh−18,357$1,615,811→ 127,183 total - Sale
Common Stock
2025-12-08$89.43/sh−3,929$351,356→ 123,254 total - Sale
Common Stock
2025-12-08$90.12/sh−8,562$771,630→ 114,692 total - Sale
Common Stock
2025-12-08$91.46/sh−3,300$301,831→ 111,392 total - Sale
Common Stock
2025-12-08$92.19/sh−1,400$129,066→ 109,992 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-12-08−49,307→ 34,083 totalExercise: $5.33Exp: 2030-05-13→ Common Stock (49,307 underlying)
Footnotes (7)
- [F1]These transactions were effected pursuant to a Rule 10b5-1 trading plan dated June 2, 2025 adopted by the reporting person.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $86.77 to $87.76, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.77 to $88.66, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.87 to $89.86, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $89.905 to $90.67, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F6]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.04 to $92.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F7]The shares underlying this stock option are fully vested and exercisable.
Documents
Issuer
Kymera Therapeutics, Inc.
CIK 0001815442
Entity typeother
Related Parties
1- filerCIK 0001821198
Filing Metadata
- Form type
- 4
- Filed
- Dec 7, 7:00 PM ET
- Accepted
- Dec 8, 6:09 PM ET
- Size
- 18.0 KB